Department of Prevention and Public Health, Faculty of Earth and Life Sciences, VU University Amsterdam, Amsterdam, The Netherlands.
PLoS One. 2010 Apr 1;5(4):e9971. doi: 10.1371/journal.pone.0009971.
There is a well recognized association between depression and diabetes. However, there is little empirical data about the prevalence of depressive symptoms and anxiety among different groups of glucose metabolism in population based samples. The aim of this study was to determine whether the prevalence of increased levels of depression and anxiety is different between patients with type 2 diabetes and subjects with impaired glucose metabolism (IGM) and normal glucose metabolism (NGM).
METHODOLOGY/PRINCIPAL FINDINGS: Cross-sectional data from a population-based cohort study of 2667 residents, 1261 men and 1406 women aged 40-65 years from the Hoorn region, the Netherlands. Depressive symptoms and anxiety were measured using the Centre for Epidemiologic Studies Depression Scale (CES-D, score >or=16) and the Hospital Anxiety and Depression Scale--Anxiety Subscale (HADS-A, score >or=8), respectively. Glucose metabolism status was determined by oral glucose tolerance test. In the total study population the prevalence of depressive symptoms and anxiety for the NGM, IGM and type 2 diabetes were 12.5, 12.2 and 21.0% (P = 0.004) and 15.0, 15.3 and 19.9% (p = 0.216), respectively. In men, the prevalence of depressive symptoms was 7.7, 9.5 and 19.6% (p<0.001), and in women 16.4, 15.8 and 22.6 (p = 0.318), for participants with NGM, IGM and type 2 diabetes, respectively. Anxiety was not associated with glucose metabolism when stratified for sex. Intergroup differences (NGM vs. IGM and IGM vs. type 2 diabetes) revealed that higher prevalences of depressive symptoms are mainly manifested in participants with type 2 diabetes, and not in participants with IGM.
Depressive symptoms, but not anxiety are associated with glucose metabolism. This association is mainly determined by a higher prevalence of depressive symptoms in participants with type 2 diabetes and not in participants with IGM.
抑郁和糖尿病之间存在公认的关联。然而,在基于人群的样本中,关于不同葡萄糖代谢群体中抑郁症状和焦虑的患病率的实证数据很少。本研究的目的是确定 2 型糖尿病患者与葡萄糖代谢受损(IGM)和正常葡萄糖代谢(NGM)患者之间是否存在不同程度的抑郁和焦虑患病率。
方法/主要发现:这是一项来自荷兰霍恩地区 2667 名 40-65 岁居民的基于人群的队列研究的横断面数据,其中 1261 名男性和 1406 名女性。使用中心流行病学研究抑郁量表(CES-D,得分≥16)和医院焦虑和抑郁量表-焦虑子量表(HADS-A,得分≥8)分别测量抑郁症状和焦虑。通过口服葡萄糖耐量试验确定葡萄糖代谢状态。在总研究人群中,NGM、IGM 和 2 型糖尿病患者的抑郁症状和焦虑患病率分别为 12.5%、12.2%和 21.0%(P=0.004)和 15.0%、15.3%和 19.9%(p=0.216)。在男性中,NGM、IGM 和 2 型糖尿病患者的抑郁症状患病率分别为 7.7%、9.5%和 19.6%(p<0.001),女性分别为 16.4%、15.8%和 22.6%(p=0.318)。当按性别分层时,焦虑与葡萄糖代谢无关。组间差异(NGM 与 IGM 和 IGM 与 2 型糖尿病)表明,抑郁症状的高患病率主要表现在 2 型糖尿病患者中,而不是在 IGM 患者中。
抑郁症状,但不是焦虑与葡萄糖代谢有关。这种关联主要是由 2 型糖尿病患者中抑郁症状的患病率较高决定的,而不是由 IGM 患者决定的。